Understanding what to patent versus what to keep as a trade secret is an increasingly important and challenging decision facing companies developing biologics products, such as cell and gene therapies, where technologies are...more
11/15/2024
/ Biologics ,
Business Model ,
Damages ,
Discovery ,
Food and Drug Administration (FDA) ,
Healthcare ,
Injunctive Relief ,
Life Sciences ,
Non-Disclosure Agreement ,
Patent Infringement ,
Patent-Eligible Subject Matter ,
Patents ,
Reverse Engineering ,
Trade Secrets
Patent term extension (PTE) provides additional patent term for patents related to U.S. pharmaceutical products to compensate for the effective loss of patent term caused by delay during the drug approval process by the U.S....more
The Federal Circuit continues to tighten the standards for written description of functional claims, particularly in the biologics realm, which is putting patent applicants in the position of having to pursue narrow claims...more
Genus claims have long been an important component of patent strategy, extending coverage around a lead compound to stop would-be competitors. Recent decisions from the Federal Circuit, however, highlight a tightening...more